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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a respiratory inflammatory
condition with autoimmune features including IgG autoantibodies. In this study we analyze the
complexity of the autoantibody response and reveal the nature of the antigens that are recognized
by autoantibodies in COPD patients.
Methods: An array of 1827 gridded immunogenic peptide clones was established and screened
with 17 sera of COPD patients and 60 healthy controls. Protein arrays were evaluated both by
visual inspection and a recently developed computer aided image analysis technique. By this
computer aided image analysis technique we computed the intensity values for each peptide clone
and each serum and calculated the area under the receiver operator characteristics curve (AUC)
for each clone and the separation COPD sera versus control sera.
Results: By visual evaluation we detected 381 peptide clones that reacted with autoantibodies of
COPD patients including 17 clones that reacted with more than 60% of the COPD sera and seven
clones that reacted with more than 90% of the COPD sera. The comparison of COPD sera and
controls by the automated image analysis system identified 212 peptide clones with informative
AUC values. By in silico sequence analysis we found an enrichment of sequence motives previously
associated with immunogenicity.
Conclusion: The identification of a rather complex humoral immune response in COPD patients
supports the idea of COPD as a disease with strong autoimmune features. The identification of
novel immunogenic antigens is a first step towards a better understanding of the autoimmune
component of COPD.
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Chronic obstructive pulmonary disease (COPD) is a com-
mon pulmonary affection, which is characterized by a
range of pathophysiological changes including airflow
limitation based on an obstructive bronchiolitis and per-
sistent inflammation with neutrophils, macrophages, B
and T lymphocytes and dendritic cells, a mucociliary dys-
function, apoptosis, and on structural changes in the air-
ways causing emphysema, and by extrapulmonary
systemic effects [1-3]. The overall global prevalence of
COPD in adults that are 40 years or older is approximately
10% [4]. While COPD is currently the fourth leading
cause of death worldwide it is expected to be the third
leading cause of death in 2020 [5]. Besides, COPD is a
major factor for disease-related loss of quality of life,
health expenditure and loss of productivity.
Various host and environmental risk factors are supposed
to contribute to the development of COPD. Host factors
include airway hyperresponsiveness and aberrant lung
growth. Several candidate genes are found to contribute to
the individual risk. Environmental risk factors include
smoking as the first cause followed by air pollution and
occupational dust or chemicals [6].
COPD shares many clinical and pathophysiological fea-
tures with autoimmune diseases [7]. There is strong evi-
dence for an active adaptive T-cell response in COPD
patients [8]. Antielastin antibody and T-helper type 1
responses characterize emphysema as an autoimmune
disease [9]. The most recent evidence for a prevalence of
IgG autoantibodies in COPD patients further supports the
idea of a strong autoimmune component in COPD [10].
However, there is rather limited information on the
nature of antigens reacting with autoantibodies in COPD
patients. In this study we identified a large number of dif-
ferent antigens immunogenic in COPD patients and
determined how many antigens reacted with each COPD
serum. Likewise, we determined how many COPD sera
reacted with each antigen. Additionally, we compared the
reactivity of each antigen between COPD sera and control
sera of healthy individuals. The identification of novel
immunogenic antigens that allow differentiation of
COPD patients from controls is a first step towards the
development of new diagnostics and therapies as recently
suggested [10].
Methods
Patient's sera
Blood samples were obtained from the Departments of
Pneumology and Hemostaseology of the Saarland Uni-
versity with patients' informed consent. Serum was iso-
lated from the blood samples and stored as aliquots at -
70°C. The patient sera stem from 17 patients with COPD.
Spirometrical data and data on smoking behavior are
summarized in Table 1. Control sera were obtained from
60 healthy blood donors. None of the included blood
donors suffered from pre-existing diseases according to
their medical records and as determined by medical exam-
ination prior to blood drawing. Information on gender
and age of all blood donors is given in Table 2.
Protein macroarray screening
We assembled 1827 different immunogenic clones from
high-density protein macroarrays consisting of 38,016 E.
coli expressed proteins from the hex1 library [11] by carry-
Table 1: Information on COPD patients
patient diagnose sex age GOLD FeV1 % BMI smoking behaviour
1 COPD, Emphysema m 63 GOLD IV 26,5 18,6 former smoker, 100 py
2 COPD f 72 GOLD II 75,7 27,5 former smoker, py unknown
3 COPD, Emphysema f 77 GOLD IV 33,7 18,6 former smoker, 30 py
4 COPD f 54 COPD IV tracheotomy 23,4 former smoker, py unknown
5 COPD f 55 GOLD III 45,6 21,4 40 py
6 COPD, Emphysema m 67 GOLD IV 28,7 29,3 former smoker, py unknown
7 COPD, Emphysema f 71 GOLD IV 30,3 27,4 former smoker, 50 py
8 COPD, Emphysema f 55 GOLD IV 17,3 22,9 former smoker, py unknown
9 COPD f 71 GOLD II 64,7 34,3 former smoker, 100 py
10 COPD f 56 GOLD IV 15,3 20,7 former smoker, 20 py
11 COPD f 57 GOLD IV 21,2 21,7 former smoker, 20–25 py
12 COPD m 80 GOLD III 39,9 24,3 120 py
13 COPD f 69 GOLD IV 21,3 30,4 former smoker, 120 py
14 COPD m 55 GOLD IV 28,7 21,2 former smoker, 30 py
15 COPD f 73 GOLD II 55,6 42 former smoker, 20 py
16 COPD m 59 GOLD IV 27,5 21 former smoker, 30 py
17 COPD, Emphysema f 52 GOLD IV 20,1 12,5 former smoker, 30 py
Definition of abbreviations: COPD = chronic obstructive pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; m = 
male; f = female; FeV1 = forced expiratory volume in one second; BMI = Body Mass Index; py = pack yearsPage 2 of 7
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human diseases. These 1827 E. coli expressed proteins
were screened in duplicates with 17 COPD sera and 60
normal control sera. In brief, macroarrays were washed
twice with TBSTT (TBS, 0.05% Tween 20, 0.5% Triton X-
100) and 4 times with TBS. After blocking with 3% non-
fat dry milk powder in TBST (TBS, 0.05% Tween 20), mac-
roarrays were incubated over night with sera 1:1000
diluted in blocking solution (3% non-fat dry milk powder
in TBST). After the incubation, sera were stored for the sec-
ond incubation round. Three washing steps with TBST
were followed by incubation with stripping solution at
70°C. Macroarrays were washed twice with TBST and 4
times with TBS. Incubation with blocking solution was
followed by a second round of serum incubation over
night. Macroarrays were washed three times with TBST,
and incubated with secondary antibody (rabbit anti-
human IgG, IgA, IgM-Cy5 (H+L)) 1:1000 diluted in
blocking solution. Macroarrays were washed four times
with TBST, twice with TBS and scanned by the GE Health-
care Typhoon 9410 scanner. The evaluation of the
scanned protein arrays was carried out by the image ana-
lyzing software tool AIDA version 4.15 and by a newly
developed computer-aided analysis procedure.
Computational analysis of seroreactivity patterns
Since manual inspection offers only a subjective and
binary analysis of reacting clones, we developed an auto-
mated image analysis procedure. After hybridizing the
arrays with the different sera, our approach computes the
intensity value for each clone on the arrays. Since all
clones were spotted in duplicates, the mean value of the
two replicates was assigned to each clone. The evaluated
antibody profiles were normalized using quantile normal-
ization to minimize between-array-effects. To access the
"value" of an antigen with respect to its ability to separate
COPD sera from control sera, we calculated the area under
the Receiver Operator Characteristics curve (AUC) for
each antigen A as follows: the normalized intensities of all
control and COPD sera were used as threshold values. For
all thresholds t, we considered COPD sera with intensity
value above t as true positives (TP), COPD sera with inten-
sity value below t as false negatives (FN), control sera with
intensity value below t as true negatives (TN), and control
sera with intensity value above t as false positives (FP).
Likewise for all thresholds, specificity (TN/(TN+FP)) and
sensitivity (TP/(TP+FN)) were computed. Please note that
in some cases the classification has to be inverted. In these
cases, diseased sera with intensity value below t are con-
sidered as 'true positives' (TP). The Receiver Operator
Characteristics (ROC) curve shows the specificity as func-
tion of one minus the sensitivity. AUC values can range
from 0 to 1. An AUC of 0.5 for a spot means that the dis-
tribution of intensity values of COPD sera and control
sera can not be distinguished. The more the AUC value of
an antigen differs from 0.5, the better this antigen is suited
to separate between the two serum groups COPD and
control. AUCs of 1 or 0 correspond to a perfect separation
of spots generated by COPD and control sera. Antigens
with AUC values > 0.5 show higher intensity values in
COPD sera than in control sera. Antigens with AUC values
< 0.5 show higher intensity values in control sera than in
COPD sera. A graphical representation of the AUC value
computation is provided in Figure 1.
Table 2: Gender and age of patients and controls
COPD sera normal sera
number 17 60
male (%) 29.4 68.3
female (%) 70.6 31.7
age, mean 63.9 38.7
The separation of intensity values of COPD and control sera is exemplarily shown for an rbitrary antigen AFigure 1
The separation of intensity values of COPD and con-
trol sera is exemplarily shown for an arbitrary anti-
gen A. A: Intensity values of each single COPD (1) and 
control (0) serum for antigen A are exemplarily shown. The 
position of the threshold (vertical green bar (2)) determines 
the number of true positives (TP), true negatives (TN), false 
positives (FP) and false negatives (FN). The vertical bars 1 
and 3 indicate the minimal and maximal thresholds. B: The 
two curves represent density estimations of intensity values 
of COPD patients (red curve) and controls (black curve) for 
antigen A corresponding to Figure 1A. C: The specificity (TN/
(TN+FP)) and sensitivity (TP/(TP+FN)) of a test are visual-
ized by the receiver operator characteristics (ROC) curve. 
The performance of the test can be represented by the area 
under the ROC curve (AUC). Here, the threshold is repre-
sented by the green circle. The values for sensitivity and spe-
cificity can be modified by moving the threshold.Page 3 of 7
(page number not for citation purposes)
Respiratory Research 2009, 10:20 http://respiratory-research.com/content/10/1/20Results
Visual analysis of protein macroarrays
Out of a fetal brain cDNA expression library encompass-
ing more than 38,000 different peptide clones, we com-
piled a set of 1827 immunogenic clones by screening
serum pools of various human diseases. To identify anti-
gens reactive with COPD sera, these peptide clones were
screened with 17 sera of patients with COPD and a con-
trol group of 60 sera of healthy blood donors. An example
of a protein macroarray analyzed with serum is shown in
Figure 2. The reactivity of each peptide clone was analyzed
by visual evaluation utilizing the image analyzing soft-
ware AIDA. Each COPD serum detected on average 63
peptide clones. The six most reactive sera identified more
than 70 peptide clones per serum and the three least reac-
tive sera identified less than 40 peptide clones per serum.
In total, all 17 sera together detected 381 different peptide
clones that reacted with autoantibodies of COPD patients.
Next, we asked how frequent does any of the peptide
clones react with sera of COPD patients. We detected 17
clones that reacted with more than 60% of all tested
COPD sera and seven clones that reacted with more than
90% of all tested COPD sera.
Computational comparison between COPD sera and 
controls
Autoantibodies are not only found in diseased persons
but are also common in healthy individuals. Therefore we
analyzed the seroreactivity of antigens not only for COPD
patients, but also for healthy blood donors as controls. To
perform a low biased evaluation of the arrayed antigens,
we utilized our newly developed computer-aided image
analysis procedure. This automated evaluation approach
allows to compare the seroreactivity of COPD and con-
trols for each antigen. We computed the area under the
Receiver Operator Characteristics curve (AUC) by com-
paring seroreactivity (intensity values) of COPD and con-
trol sera for each clone. The overall distribution of AUC
values for all 1827 clones is shown in Figure 3. In the fol-
lowing we only examined clones with AUC values < 0.3 or
> 0.7 because these clones are best suited to separate
COPD from control sera. We found 212 peptide clones,
including 67 clones that represent in frame sequences and
145 peptide clones that represent out of frame sequences.
The 67 in frame clones represent 58 different genes. Com-
parison of the autoantibody profiles between male and
female controls did not show a statistically significant
influence of gender. Likewise, we did not find a significant
influence of the age on the autoantibody profiles of nor-
mal controls (data not shown).
The best clone (AUC = 0.10) showed sequence homology
to FAM36A but represents an out of frame sequence. The
spot intensities of clone FAM36A for all sera and the dis-
tribution (frequency) of seroreactivity signals according to
the spot intensities are shown in Figure 4. The best in
frame clone (AUC = 0.87) showed sequence homology to
MCM3 that has been identified as immunogenic antigen
in colon and prostate cancer. The above mentioned clone
FAM36A showed higher immunogenicity in control sera
than in COPD sera. Clone MCM3, the best in frame clone,
showed higher immunogenicity in COPD sera than in
control sera (see Figure 5). In total, 40 of the 67 in frame
clones showed higher immunogenicity in COPD sera
Example for a protein macroarray analyzed with serumFigure 2
Example for a protein macroarray analyzed with 
serum. Since all clones are spotted in duplicate, any antigen 
– antibody reactivity is indicated by two signals.
Frequency of antigens according to their AUC valueigur  3
Frequency of antigens according to their AUC value. 
AUC values of all antigens were calculated for the classifica-
tion COPD sera versus control sera. The distribution dem-
onstrates a large number of antigens with AUCs < 0.3 and > 
0.7.Page 4 of 7
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clones showed higher immunogenicity in control sera
than in COPD sera. In addition, 17 clones showed homol-
ogy to proteins that were identified as immunogenic anti-
gens in various human cancers http://ludwig-
sun5.unil.ch/CancerImmunomeDB/. These proteins
included NME2, CDC42BPB, RPS2, PTBP1, SON, MCM3,
CD320, VIM, CENPB, PDE4DIP, CCNL2, HMG-14,
HSPD1, MAZ, RPL6, STUB1, and MBTPS1. Antigens
YBX1, HMG-14, and CENPB which showed also informa-
tive AUC values are involved in the autoimmune disease
systemic sclerosis. CENPB was additionally associated
with the autoimmune diseases lupus erythematosus and
rheumatoid arthritis [12-15]. Clones with homology to
TRAF4 and NME2 have previously been associated with
non-cancer lung diseases. More information on all 67
clones is summarized in Additional file 1.
In silico analysis of the in frame peptide clones
Sequence motives like coiled coil, ELR, RGD, and
granzyme B cleavage sites can be characteristic for autoan-
tigens [16-18]. We analyzed the 58 different genes with
the statistical gene analysis tool "GeneTrail" [19]. Our
analysis revealed that 20.7% of the 58 sequences are con-
taining coiled coil motives, whereas only 11.3% of all
human gene sequences show such motives. We found
approximately 10% more sequences with ELR motives in
our test set, i.e. the 58 genes, as compared to the training
set. Predicted granzyme B cleavage sites were found in
43.1% of the sequences in our test set and in 40.4% of the
sequences in the reference set. In contrast, RGD motives
were found in only 5.2% of the sequences in our test set
but in 7.5% of the sequences in the reference set.
Out of the 58 genes, eight genes namely RPL37, RPL35,
RPS27A, RPL23A, RPL6, RPS2, RPS6, and LOC388720are
involved in the KEGG (Kyoto Encyclopaedia of Genes and
Genomes) ribosome pathway. RPS6 is also involved in
the insulin signalling and the mTOR signalling pathway.
MCM3 and VIM are involved in the pathways cell cycle
and cell communication, respectively. GTF2B, also known
as TFIIB, is a member of the pathway basal transcription
factors. HSPD1 is involved in the two pathways Prion dis-
ease and Type I diabetes mellitus.
Discussion
The concept of COPD as an autoimmune disease is sup-
ported by the recent findings of frequent IgG autoreactive
antibodies in COPD patients [7-10]. In our study, we
identified 381 antigens that are immunogenic in COPD
patients by screening protein macroarrays with patients'
sera followed by a visual evaluation. We identified seven
Intensity values of FAM36A shown for all COPD and control seraFigure 4
Intensity values of FAM36A shown for all COPD and 
control sera. A: FAM36A intensity values shown for each 
serum. Blue circles indicate sera of COPD patients and red 
circles indicate control sera. B: Distribution of seroreactivity 
signals according to their intensities. Seroreactivity signals 
that stem from controls are indicated in blue, and seroreac-
tivity signals that stem from COPD sera are indicated in 
green. The overlaps are indicated in yellow. For this clone, 
signals with low intensities are mostly found with COPD sera 
and signals with higher intensities are mostly found with con-
trol sera. Intensity values of MCM3 shown for all COPD and control seraFigure 5
Intensity values of MCM3 shown for all COPD and 
control sera. A: MCM3 intensity values shown for each 
serum. Sera of COPD patients are indicated by blue circles 
and control sera are indicated by red circles. For this clone, 
signals with low intensities are mostly found with control 
sera and signals with higher intensities are mostly found with 
COPD sera. B: Example of seroreactivity signals. The posi-
tion of the analyzed clone is indicated by red rectangles. Each 
clone of the array is spotted in duplicate. By visual analysis, 
this clone was found positive with all shown COPD sera and 
negative with all shown normal sera.Page 5 of 7
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sera. To overcome a bias possibly caused by visual evalua-
tion of the protein macroarrays, we additionally evaluated
the macroarrays with a computer aided image analysis
procedure that ensures a standardized evaluation of the
arrays. Here, we identified 212 peptide clones with
informative AUC values < 0.3 and > 0.7 by comparing
seroreactivities of COPD patients and healthy controls.
Clones with informative AUC values offer themselves as
future biomakers for COPD. The identification of biomar-
kers is however not the focus of our study. Biomarker eval-
uation requires a study design that tests antigens with
informative AUC values for their reactivity against a large
number of patients' sera and control sera in a prospective
manner. The identified peptide clones provide the basis
for such a prospective study. The clones with AUC < 0.3
and > 0.7 included 67 in frame clones, representing 58
different genes and 145 out of frame clones that are
termed mimotopes. Mimotopes are defined as peptides
capable of binding to the antibody but unrelated in
sequence to the natural protein that the antibody recog-
nizes [20]. Since some of the mimotopes yielded rather
informative AUC values as for example clone FAM36A, it
will be worthwhile to reveal the nature of the natural pro-
tein that react in vivo with autoantibodies of COPD
patients.
As indicated above a larger number of clones identified in
this study were previously associated with an immune
response in cancer or with autoimmune diseases. In addi-
tion, the two genes TRAF4 and NME2 have been associ-
ated with non-cancer lung diseases. TRAF4 deficiency
leads to tracheal malformation resulting in airflow limita-
tions in TRAF4-deficient mice [21]. NME2 negatively reg-
ulates Rho activity through interactions with other
proteins involved in the Rho pathway [22]. In embryonic
mouse lungs, the inhibition of the Rho pathway leads in
vitro to reduced lung bud formation after 48 hours [23].
Since none of the clones identified in our study has previ-
ously been associated with the development or progres-
sion of COPD, the newly identified antigens may give
leads to as of yet not analyzed cellular processes underly-
ing COPD. Several of the identified antigens are currently
discussed as biomarkers including HSP1, MAZ, and RPS2
that are up-regulated in colorectal cancer, acute myeloid
leukaemia, and astrocytoma, respectively [24-26]. In addi-
tion, future biomarkers may be identified among the anti-
gens NME2, CDC42BPB, RPS2, PTBP1, SON, MCM3,
CD320, VIM, CENPB, PDE4DIP, CCNL2, HMG-14,
HSPD1, MAZ, RPL6, STUB1, and MBTPS1 all of which
have been associated with different human cancers. How-
ever, none of the identified antigens has been introduced
into clinical practice.
It remains to elucidate what mechanisms contribute to the
immunogenicity of each antigen in COPD patients. One
hypothesis is that the humoral immune response against
disease associated antigens results from overexpression.
Although there is some evidence for an association of
overexpression and immunogenicity of antigens [27,28],
conclusive experimental proof for a causative role of over-
expression has still to be provided. Posttranslational mod-
ifications including altered protein folding and processing
may also cause a humoral immune response against dis-
ease-associated antigens. In addition, mutations are dis-
cussed as cause for the humoral immune response against
immunogenic antigens [29]. However, we analyzed the
reactivity of COPD sera using a cDNA library expressed in
E. coli that lack the post-translational modification
machinery. In addition, the sequences are highly unlikely
to contain specific COPD mutations. Several sequence
motives including coiled coil, RGD, ELR and granzyme B
cleavage sites have previously been associated with the
immunogenicity of antigens [16-18]. We found a slightly
elevated percentage of coiled coil motives, ELR motives,
and granzyme B cleavage sites in COPD associated anti-
gens. Single analysis of each of these antigens will be
required to elucidate the contribution of these motives
and other factors to the immunogenicity of the antigens.
Conclusion
Our study provides clear evidence that COPD shows
strong autoimmune features. In contrast to previous stud-
ies, we not only demonstrated the prevalence of IgG
autoantibodies but determined the nature of antigens
reacting with autoantibodies in COPD patients. The iden-
tification of novel immunogenic antigens that allow dif-
ferentiation of COPD patients from healthy controls will
help to contribute to improved diagnostics and therapies.
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